Lasa Supergenerics Limited Market Cap ($2.41 Million)
Market Cap & Net Worth: Lasa Supergenerics Limited (LASA)
Lasa Supergenerics Limited market cap. Lasa Supergenerics Limited (NSE:LASA) has a market capitalization of $2.41 Million (Rs222.45 Million) as of November 5, 2026. Listed on the NSE stock exchange, this India-based company holds position #29796 globally and #1655 in its home market, demonstrating a -20.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lasa Supergenerics Limited's stock price Rs4.44 by its total outstanding shares 50101239 (50.10 Million). Also see Lasa Supergenerics Limited (LASA) cash flow conversion for how efficiently the company converts equity into cash flow.
Lasa Supergenerics Limited Market Cap History (2017–2026)
Lasa Supergenerics Limited market cap history from 2017 to 2026. Data shows change from $97.08 Million to $2.41 Million (-31.80% CAGR). Check current stock price of Lasa Supergenerics Limited for real-time trading data and today's change.
Lasa Supergenerics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lasa Supergenerics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LASA net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Lasa Supergenerics Limited's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $97.08 Million | $1.99 Billion | $23.62 Million | 0.05x | 4.11x |
| 2018 | $16.18 Million | $2.44 Billion | $123.40 Million | 0.01x | 0.13x |
| 2019 | $9.60 Million | $1.70 Billion | -$120.31 Million | 0.01x | N/A |
| 2020 | $45.39 Million | $1.67 Billion | $36.28 Million | 0.03x | 1.25x |
| 2021 | $36.93 Million | $2.02 Billion | $227.78 Million | 0.02x | 0.16x |
| 2022 | $18.23 Million | $1.37 Billion | -$53.31 Million | 0.01x | N/A |
| 2023 | $16.20 Million | $1.30 Billion | -$386.21 Million | 0.01x | N/A |
| 2024 | $13.78 Million | $1.04 Billion | -$217.31 Million | 0.01x | N/A |
| 2025 | $5.11 Million | $1.42 Billion | -$147.57 Million | 0.00x | N/A |
Competitor Companies of LASA by Market Capitalization
Companies near Lasa Supergenerics Limited in the global market cap rankings as of November 5, 2026. Also see LASA current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Lasa Supergenerics Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Lasa Supergenerics Limited (2017–2026)
Market capitalization of Lasa Supergenerics Limited from 2017 to today. Between 2017 and today, Lasa Supergenerics Limited's market cap moved from $97.08 Million to $ 2.41 Million, with a yearly change of -31.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs2.41 Million | -52.97% |
| 2025 | Rs5.11 Million | -62.89% |
| 2024 | Rs13.78 Million | -14.92% |
| 2023 | Rs16.20 Million | -11.14% |
| 2022 | Rs18.23 Million | -50.63% |
| 2021 | Rs36.93 Million | -18.63% |
| 2020 | Rs45.39 Million | +372.63% |
| 2019 | Rs9.60 Million | -40.63% |
| 2018 | Rs16.18 Million | -83.34% |
| 2017 | Rs97.08 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Lasa Supergenerics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.41 Million USD |
| MoneyControl | $2.41 Million USD |
| MarketWatch | $2.41 Million USD |
| marketcap.company | $2.41 Million USD |
| Reuters | $2.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more